Home About us Contact
|
Home About us Contact | ||
|
|
||
Gland Tumours (gland + tumour)
Kinds of Gland Tumours Selected AbstractsPaediatric intraoral mucoepidermoid carcinoma mimicking a bone lesionINTERNATIONAL JOURNAL OF PAEDIATRIC DENTISTRY, Issue 2 2007PAULO MORAES Background., Mucoepidermoid carcinoma of the salivary glands occurs most frequently in adults during the fifth and sixth decades of life. Although uncommon, it is the main malignant salivary gland tumour in children, particularly adolescents. Case report., A 14-year-old girl presented with a mass in her palate that had had a duration of one year. On panoramic X-ray, a well-delimited radiolucent area was observed on the left maxillary sinus region. The initial clinical diagnostic hypothesis was that this was a central giant cell granuloma. An incisional biopsy was performed and the final microscopic diagnosis was mucoepidermoid carcinoma. The tumour was removed by a wide transoral resection and the patient has been asymptomatic for 4 years. Conclusion., Mucoepidermoid carcinoma in paediatric patients is uncommon, but it must be considered in differential diagnoses of intraoral submucosal mass/nodules in children, particularly in the palate. [source] Cutaneous metastasis from a parotid myoepithelial carcinoma: a case report and review of the literatureJOURNAL OF CUTANEOUS PATHOLOGY, Issue 12 2008Deng-qi He Myoepithelial carcinoma of the parotid gland is a rare salivary gland tumour, and its distant cutaneous metastasis has not been reported to date. Here, we report a case of myoepithelial carcinoma of the left parotid gland, which had metastasised to the skin of the right thorax after parotidectomy and radiotherapy. Diagnosis of the primary and metastatic tumour was based on the clinical findings and was confirmed by immunohistochemistry. A literature review of the clinical features of the skin metastases of parotid malignancies and their related pathological mechanisms is included in this case study. It was noted that myoepithelial carcinoma of the parotid gland has the potential to develop distant skin metastasis, which may be indicative of widespread dissemination and poor prognosis. Attention should be paid to initial treatment of the primary tumour and to emerging cutaneous masses whose location is distant from the primary tumour during follow up. [source] 4361: Management of orbital tumours with adjuvant iodine brachytherapy using "inverted" plaquesACTA OPHTHALMOLOGICA, Issue 2010T KIVELÄArticle first published online: 23 SEP 2010 Purpose To describe our experience in using "inverted" iodine plaques as adjuvant treatment after resection of orbital tumours. Methods Between 1999 and 2007, three patients (ages 17-48 years) underwent resection of an lacrimal gland tumour followed by application of an "inverted" iodine plaque manage any microscopic infiltration, i.e. a gold plaque carrying iodine-125 seeds on its convex rather than concave surface. In a fourth instance, the seeds were placed on the convex surface of a ruthenium rather than a gold plaque to manage an eye with a late extraocular recurrence of an irradiated uveal melanoma following resection of the extension. Results The diameter of the plaque was 20 mm. It was sutured to the sclera so that when the eye was in primary position the lacrimal fossa was targeted. When the eye moved, the irradiated volume naturally enlarged. A 40-56 Gy dose was calculated to the depth of 10 mm, and the dose at 5 mm was then calculated as 80-134 Gy. Treatment time was 59-154 hours. In one case, the iodine seeds were placed asymmetrically to limit radiation damage to the eyelid skin. In two patients, transient erythema of the upper eyelid developed, which resolved in a few months time. In case of the extraocular melanoma, dose was the same. Recurrent tumours have not developed. Conclusion An "inverted" iodine plaque is one option for adjuvant irradiation of the orbit which shields the eye from radiation damage. [source] Evaluation of accuracy of fine needle aspiration cytology for diagnosis of canine mammary tumours: comparative features with human tumoursCYTOPATHOLOGY, Issue 3 2007G. D. Cassali Objective:, The authors evaluated the accuracy of the fine needle aspiration cytology technique in the diagnosis of 77 canine mammary gland tumours using the same cytological and histological criteria currently applied to the diagnosis of human breast cancer. Methods:, The study was performed in 73 pure or mixed-breed female dogs submitted to surgical resections of ,mammary tumours'. All cytological smears were stained by routine May-Grunwald,Giemsa and Papanicolaou stains. Results:, We obtained a correct cyto-histological correlation in 52/77 cases (67.5%) when all cytopathological examinations were considered, and in 52/56 cases (92.9%) when the inconclusive cases were excluded from the analysis. Conclusion:, Our results demonstrate that, because of the similarity of the cytological findings in the human and canine mammary gland tumours, it is possible to use the same cytological criteria applied in human pathology for the diagnosis of canine mammary gland tumours. [source] Eruptive syringoma: 27 new cases and review of the literatureJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Issue 3 2001J Soler-Carrillo Abstract Background Eruptive syringomas are uncommon eccrine sweat gland tumours. Only 64 cases have been reported in the literature. Objective Clinical findings of 27 patients with eruptive syringomas were reviewed over a 47-year period. Results The tumours appeared as multiple yellow,brown-coloured papules localized on the neck, anterior trunk, axillae, shoulders, abdomen or pubic area. This disorder occurs more frequently among women, and is frequent in the prepubertal as well as in the postpubertal age. The diagnosis was not clinically suspected in most cases. Conclusions Eruptive syringomas have to be considered in differential diagnosis of papular dermatosis at any age. [source] Immunohistochemical staining of cutaneous tumours with G-81, a monoclonal antibody to dermcidinBRITISH JOURNAL OF DERMATOLOGY, Issue 1 2004Y. Minami Summary Background Recently, the novel antimicrobial peptide named dermcidin (DCD) was reported in human eccrine sweat glands. Objectives We investigated the expression of DCD in a variety of cutaneous tumours in order to assess the usefulness of the monoclonal antibody (G-81), which recognizes a fragment of DCD. Patients/methods We studied the immunoreactivity of the G-81 antibody on 197 cutaneous tumours. Results A total of 13 of 26 cutaneous mixed tumours showed substantial immunoreactivity. In contrast all the following cases were completely unreactive: (i) epithelial tumours (seborrhoeic keratosis, squamous cell carcinoma, Bowen's disease, actinic keratosis, genital Paget's disease); (ii) follicular tumours (basal cell carcinoma, trichilemmoma, trichoepithelioma, trichoblastoma, keratoacanthoma, proliferating trichilemmal tumour, pilomatricoma); (iii) melanocytic tumours (malignant melanoma, naevus cell naevus, Spitz naevus, blue naevus); (iv) neural tumours (schwannoma, neurofibroma, Merkel cell neoplasm); (v) mesenchymal tumours (soft fibroma, dermatofibroma, dermatofibrosarcoma protuberans, vascular leiomyoma, leiomyosarcoma, lipoma, juvenile xanthogranuloma, angiomyoma); and (vi) other sweat gland tumours (poroid neoplasms, syringoma, cylindroma, clear cell hidradenoma, spiradenoma, syringoid eccrine carcinoma, mucinous carcinoma, apocrine cystadenoma, syringocystadenoma papilliferum, apocrine adenocarcinoma). Twenty-six cutaneous mixed tumours were considered from histopathological findings to be the apocrine type, but 13 of 26 mixed tumours contained some DCD-immunopositive cells that possibly differentiate into eccrine secretory glands. Conclusions We found the expression of DCD in tubular structures of 50% of cutaneous mixed tumours with apocrine differentiation. These results suggest that a number of cutaneous mixed tumours show both eccrine and apocrine differentiation in the same neoplasm. [source] DNA image cytometry in malignant and benign sweat gland tumoursBRITISH JOURNAL OF DERMATOLOGY, Issue 4 2000M. Vogelbruch The histopathological differentiation between well-differentiated carcinomas and atypical adenomas of sweat gland origin may be difficult, even if immunohistochemical methods are used. Therefore, additional techniques may be helpful. We previously demonstrated that DNA image cytometry (ICM-DNA) can be useful in distinguishing between malignant and benign clear cell hidradenoma. In the present study, a larger series of sweat gland tumours, with a clear-cut diagnosis as malignant or benign on histopathological criteria, was examined by ICM-DNA. Enzymatic cell separation specimens were prepared from paraffin-embedded tissues of 18 sweat gland carcinomas (14 porocarcinomas, one classic eccrine adenocarcinoma, two microcystic adnexal carcinomas and one mostly ductal apocrine carcinoma) and 47 benign sweat gland tumours (three syringocystadenomas, five spiradenomas, 14 cylindromas, three syringomas, seven nodular hidradenomas, 10 cutaneous mixed tumours, four poromas and one apocrine hidrocystoma). Specimens were examined by ICM-DNA according to the current recommendations of the European Society for Analytical Cellular Pathology with the AutoCyte QUIC-DNA workstation using mesenchymal cells as an internal reference. DNA aneuploidy was detected by the stemline interpretation according to Böcking and/or at least three 5[c]-exceeding events. DNA aneuploidy was detected in 16 of 18 (89%) of the sweat gland carcinomas, but in none of the 47 adenomas. These results suggest that the detection of DNA aneuploidy in sweat gland tumours using ICM-DNA is a clear and specific indicator of prospective malignancy. [source] Retroperitoneal endoscopic adrenalectomy is safe and effectiveBRITISH JOURNAL OF SURGERY (NOW INCLUDES EUROPEAN JOURNAL OF SURGERY), Issue 11 2010J. M. J. Schreinemakers Background: The aim of this study was to review an experience with retroperitoneal endoscopic adrenalectomy (REA). This is the procedure of choice for adrenal tumours at this institution. Methods: Between 1997 and 2008, 112 REAs were performed in a single university centre. Data were retrieved retrospectively from a prospectively collected database, including information on patient demographics, surgical procedure, complications and hospital stay. Results: One hundred and twelve REAs were carried out successfully in 105 patients, including seven bilateral adrenalectomies. Thirty-nine patients with unilateral adrenal disease had a phaeochromocytoma, of whom 16 had multiple endocrine neoplasia syndrome type 2, 21 patients had Cushing's disease and 20 had Conn's disease. Median body mass index was 27 (interquartile range 23,29) kg/m2. The median duration of unilateral operations was 100 (90,130) min with a median blood loss of 5 ml. Median tumour size was 3·1 (2·0,4·4) cm. Conversion from REA to open surgery was needed in two patients. Seven patients experienced postoperative complications (2 major, 5 minor). One patient needed a reoperation. The median postoperative hospital stay was 3 days. A learning curve with a significant decrease in operating time was observed over the years. Conclusion: REA appears to be a safe and effective surgical technique for adrenal gland tumours up to 6 cm in diameter, with a minimal complication rate. Copyright © 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. [source] 3461: Lacrimal gland: non-neoplastic and neoplastic lesions in Denmark 1974-2007ACTA OPHTHALMOLOGICA, Issue 2010S HEEGAARD Purpose To evaluate patient characteristics and incidence of lacrimal gland lesions in Denmark during the period 1974-2007. Methods All biopsied/surgically removed lacrimal gland lesions collected by the Danish pathological departments during the period 1974-2007 were identified by SNOMED codes. In each case age, gender, symptoms, clinical findings, treatment and follow-up were registered. All tumours were re-classified according to latest guidelines from WHO. Results 229 lacrimal gland lesions from 209 patients were identified during the 34-year period. In the study period 7 cases/year were registered (1.3 cases/million/year). Non-neoplastic lesions predominated with a total of 114 (50 %) with the most frequent being inflammation 63 (55%), normal lacrimal gland tissue 28 (25%) and dacryops 23 (20%). Benign tumours comprised a total of 45 (20%) with the most frequent tumour being pleomorphic adenoma 31 (69%). Malignant tumours constituted a total of 70 (31%). 52 (74%) of these were primary tumours, 9 (13%) were secondary invading tumours, 8 (11%) were local recurrences and 1 (1%) was a distant metastasis. Primary malignant tumours comprised malignant lymphoma 25 (48%) and malignant epithelial tumours 27 (52%). The most frequent malignant tumour was adenoid cystic carcinoma comprising 14 (27%) of the primary malignant tumours. Conclusion Lacrimal gland lesions are rare and primarily benign. Treatment of malignant lacrimal gland tumours should be considered a specialist treatment. [source] 3462: Epithelial tumours of the lacrimal glandACTA OPHTHALMOLOGICA, Issue 2010SE COUPLAND Purpose To provide an overview of benign and malignant epithelial neoplasms arising in the lacrimal gland. Methods In the normal orbit, the lacrimal gland is clinically impalpable and is situated in the lacrimal fossa posterior to the superotemporal orbital rim. The gland is not truly encapsulated and is divided into the deep orbital and the superficial palpebral lobes by the levator aponeurosis. The retrospective study of 265 epithelial tumours of the lac¬rimal gland conducted by the Armed Forces Institute of Pa¬thology (AFIP) improved our understanding of the histologic classification and clinical behavior of epithelial tumours of the lacrimal gland. The historic works of Forrest (1954) and Zimmerman (1962) alleviated confu¬sion by applying to epithelial tumours of the lacrimal gland the histopathologic classification of salivary gland tumours. Epithelial tumours originating from the lacrimal gland should be staged according to the 7th Edition of the Tumor Node Metastasis (TNM) system, which is a modification of the World Health Organization (WHO) classification of salivary gland tumours. Results The most common benign epithelial tumour of the lacrimal gland is the pleomorphic adenoma. The most common lacrimal gland carcinomas include adenoid cystic carcinoma, "carcinoma ex pleomorphic adenoma", primary adenocarcinoma & mucoepidermoid carcinoma. The regional lymph nodes include: preauricular, submandibular and cervical lymph nodes. The lung is the most common metastatic site, followed by bone and remote viscera. Conclusion Subtyping & grading of lacrimal gland epithelial tumours requires the latest WHO/AFIP classifications. Staging of these tumours should follow the 7th TNM system. Collection of datapoints is essential to identify biomarkers, which includes only nuclear N23 and MIB-1 at present. [source] 3464: Surgical treatment of lacrimal gland tumoursACTA OPHTHALMOLOGICA, Issue 2010D BRISCOE Purpose The surgical treatment of Lacrimal gland tumors is often controversial and not so clear cut. Imaging and a full systemic evaluation lead to the decision as to which surgical approach best serves our purposes. The surgical management of Lacrimal gland tumors is discussed and the results of 31 cases in my experience are presented. Methods The surgical approach used is carefully chosen according to the type of disease presentation. All 31 patients in this series had neuroimaging and full work up and 30 underwent incision or excision biopsy. Selected cases are discussed. Results : Surgical Approaches chosen for the Lacrimal gland in this case series included Trans-Septal Orbitotomy, and Lateral Orbitotomy. Disease spectrum included Idiopathic orbital inflammatory disease (8), Orbital Sarcoid (7), Lymphoma (3), Sjrogens disease (3), Benign Mixed Tumour (2), Infectious mononucleosis (2) Angiolymphoid Hyperplasia (2), Sebaceous Cell Carcinoma (1), Churge Strause syndrome (1), Dermoid Cyst (1), Epithelial Inclusion Cyst(1). Conclusion Biopsy of a Lacrimal gland mass is relatively simple and is recommended. The approach should be considered carefully and an excision biopsy should be performed where possible. Surgical management and surprising pathology results can have significant implications for the patient. [source] 3465: Medical cancer therapy of lacrimal gland tumoursACTA OPHTHALMOLOGICA, Issue 2010C LE TOURNEAU Purpose The most common malignant epithelial cancer of the lacrimal gland is the adenoid cystic carcinoma (ACC). Despite a slow growth, ACCs are ultimately associated with a poor outcome. Methods Given the rarity of this disease, there are actually no conclusive recommendations for optimal therapy of this tumor. Results Surgery and postoperative radiation therapy is commonly used in the initial local treatment of ACC of the lacrimal gland. In high-risk recurrence patients, concomitant platinum-based chemoradiation should be discussed in an attempt to enhance radiosensitivity. While encouraging responses were reported with intraarterial neoadjuvant chemotherapy, this strategy was associated with substantial toxicity and should not be recommended outside of clinical trials. In the metastatic setting, systemic therapy is the only available option if no surgery and/or radiation is feasible. Although some tumour shrinkage has been reported with intravenous chemotherapy, only dismal objective response rates were achieved. Most active drugs remain anthracyclines and platinum compounds. Drug combinations do not seem to add much efficacy. More recently, non-cytotoxic molecularly targeted agents have emerged and demonstrated significant efficacy in several tumour types. These agents modulate specific targets thought to be essential for tumour proliferation and/or angiogenesis. c-KIT, PDGFR,, EGFR, and VEGFR are transmembrane receptors with oncogenic tyrosine kinase activity that are commonly overexpressed in ACC. The use of drugs triggering these targets has been disappointing so far. Conclusion The recent identification of a hallmark gene fusion transcript thought to activate critical targets involved in apoptosis, cell cycle control, cell growth and angiogenesis, heralds new treatment promise. [source] | ||||||||||